Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

cefdinir (Rx)Brand and Other Names:

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

capsule

  • 300mg

oral suspension

  • 125mg/5mL
  • 250mg/5mL
more...

Community-Acquired Pneumonia

Disease caused by Haemophilus influenzae (including beta-lactamase-producing strains), Haemophilus parainfluenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including beta-lactamase-producing strains)

300 mg PO q12hr for 10 days

Respiratory Tract Infections

Acute exacerbations of chronic bronchitis caused by H influenzae (including beta-lactamase-producing strains), H parainfluenzae (including beta-lactamase-producing strains), S pneumoniae (penicillin-susceptible strains only), or M catarrhalis (including beta-lactamase-producing strains); pharyngitis and tonsillitis caused by Streptococcus pyogenes

300 mg PO q12hr for 5-10 days or 600 mg PO q24hr for 10 days

Acute Maxillary Sinusitis

Disease caused by H influenzae (including beta-lactamase-producing strains), S pneumoniae (penicillin-susceptible strains only), or M catarrhalis (including beta-lactamase-producing strains)

300 mg PO q12hr or 600 mg PO q24hr for 10 days

Skin/Skin Structure Infections

Uncomplicated infections caused by Staphylococcus aureus (including beta-lactamase-producing strains) or S pyogenes

300 mg PO q12hr for 10 days

Dosing Modifications

Renal impairment

  • CrCl <30 mL/min (adults): Not to exceed 300 mg/day PO
  • CrCl <30 mL/min (children): 7 mg/kg PO q24hr; not to exceed 300 mg/day

Hepatic impairment

  • No dosage adjustment necessary

Dosage Forms & Strengths

capsule

  • 300mg

oral suspension

  • 125mg/5mL
  • 250mg/5mL
more...

Acute Bacterial Otitis Media

Disease caused by H influenzae (including beta-lactamase-producing strains), S pneumoniae (penicillin-susceptible strains only), or M catarrhalis (including beta-lactamase-producing strains)

<6 months: Safety and efficacy not established

6 months-12 years: 7 mg/kg PO q12hr for 5-10 days or 14 mg/kg PO q24hr for 10 days 

Pharyngitis/Tonsillitis

Disease caused by S pyogenes

<6 months: Safety and efficacy not established

6 months-12 years: 7 mg/kg PO q12hr for 5-10 days or 14 mg/kg PO q24hr for 10 days  

>12 years or >43 kg: 300 mg PO q12hr for 5-10 days or 600 mg PO q24hr for 10 days

Acute Maxillary Sinusitis

Disease caused by H influenzae (including beta-lactamase-producing strains), S pneumoniae (penicillin-susceptible strains only), or M catarrhalis (including beta-lactamase-producing strains)

<6 months: Safety and efficacy not established

6 months-12 years: 7 mg/kg PO q12hr or 14 mg/kg PO q24hr for 10 days  

>12 years or >43 kg: 300 mg PO q12hr or 600 mg PO q24hr for 10 days

Skin/Skin Structure Infections

Uncomplicated infections caused by S aureus (including beta-lactamase-producing strains) or S pyogenes

<6 months: Safety and efficacy not established

6 months-12 years: 7 mg/kg PO q12hr for 10 days 

>12 years or >43 kg: 300 mg PO q12hr for10 days

Administration

Coadministration with iron-containing supplements

  • Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements
  • Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula
  • Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract
Next

Interactions

Interaction Checker

cefdinir and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Diarrhea (8-15%)

            1-10%

            Vaginal moniliasis (<4%)

            Nausea (3%)

            Rash (3%)

            Headache (2%)

            Increased urine leukocytes (2%)

            Increased urine protein (1-2%)

            Decreased lymphocytes (1%)

            Glycosuria (1%)

            Increased alkaline phosphatase (1%)

            Increased eosinophils (1%)

            Increased platelets (1%)

            Previous
            Next

            Warnings

            Contraindications

            Documented hypersensitivity

            Cautions

            Note differences between twice-daily and once-daily dosing regimens

            Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy

            Dosage adjustments may be necessary if CrCl is <30 mL/min

            Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy

            Use caution in patients with history of colitis

            Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid

            Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: B

            Lactation: Unknown whether drug is excreted in milk

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Third-generation cephalosporin; inhibits mucopeptide synthesis in bacterial cell wall; typically bactericidal, depending on organism susceptibility, dose, and serum or tissue concentrations

            Absorption

            Bioavailability: 16-21% (capsule); 25% (suspension)

            Peak plasma time: 2-4 hr

            Plasma protein: 60-70%

            Distribution

            Distributed into blister fluid, middle-ear fluid, tonsils, sinus tissue, bronchial mucosa, epithelial lining fluid

            Vd: 0.29-1.05 L/kg (6 months-12 years); 0.06-0.64 L/kg (adults)

            Metabolism

            Not appreciably metabolized

            Elimination

            Half-life: 100 min

            Excretion: Urine (7-25% as unchanged drug)

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.